Impact of PLA2G2A rs11573156 C > G Variant on Phospholipase Expression and Metastatic Behavior in Prostate Cancer
Gene · 2025
DOI: 10.1016/j.gene.2025.149641 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gene, 2025. Verfasst von Ipek Bedir und 2 weiteren Autor:innen. Beteiligte Einrichtung: Yeditepe University, Department of Genetics and Bioengineering, Istanbul, Turkey. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Group II Phospholipases A2, Polymorphism, Single Nucleotide. Die Arbeit nennt 60 Literaturangaben.
Abstract (Originalsprache)
Prostate cancer (PCa) is a major global health concern and a leading cause of cancer-related deaths in men. Despite available treatments, PCa frequently recurs and exhibits high metastatic potential. One key factor in its malignancy is PLA2G2A, a secretory phospholipase A2 enzyme with strong inflammatory properties. Elevated PLA2G2A levels in the bloodstream have been linked to tumor grade, potentially due to the rs11573156 C > G polymorphism in the gene's 5' untranslated region (5'UTR). Previously, we demonstrated that individuals carrying the G allele have a 2.5-fold lower risk of developing metastatic PCa compared to those with the C allele. To further investigate the functional impact of this polymorphism, we employed CRISPR-Cas9 base editing to convert the GC genotype of metastatic PC-3 prostate cancer cells into the homozygous GG genotype. Our findings indicate that the G allele enhances PLA2G2A expression while downregulating genes associated with epithelial-to-mesenchymal transition (EMT), an effect reversed upon siRNA-mediated PLA2G2A silencing. Furthermore, this genetic alteration impaired the migratory capacity of PC-3 cells following interferon-γ (IFN-γ) priming, simulating an inflammatory tumor microenvironment. Notably, siRNA-induced downregulation of PLA2G2A reversed the anti-migratory effects associated with the GG genotype. Our results suggest that increased PLA2G2A expression, driven by the G allele, negatively affects cell proliferation, EMT, and metastatic properties, underscoring its potential anti-tumor role in PCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Yeditepe University, Department of Genetics and Bioengineering, Istanbul, Turkey.
- Yeditepe University, Department of Genetics and Bioengineering, Istanbul, Turkey; University of Münster, Institute of Cellular Virology (ICV), Münster, Germany.
- Yeditepe University, Department of Genetics and Bioengineering, Istanbul, Turkey. Electronic address: dilek.telci@yeditepe.edu.tr.
Zitieren
APA
Bedir, I., Ozturk, K., & Telci, D. (2025). Impact of PLA2G2A rs11573156 C > G Variant on Phospholipase Expression and Metastatic Behavior in Prostate Cancer. Gene. https://doi.org/10.1016/j.gene.2025.149641
Vancouver
Bedir I, Ozturk K, Telci D. Impact of PLA2G2A rs11573156 C > G Variant on Phospholipase Expression and Metastatic Behavior in Prostate Cancer. Gene. 2025. doi:10.1016/j.gene.2025.149641
BibTeX
@article{Bedir2025,
author = {Bedir, Ipek and Ozturk, Kaan and Telci, Dilek},
title = {Impact of PLA2G2A rs11573156 C > G Variant on Phospholipase Expression and Metastatic Behavior in Prostate Cancer},
journal = {Gene},
year = {2025},
doi = {10.1016/j.gene.2025.149641}
}
EUVIMED